Category:

Release – Schwazze Signs Definitive Documents to Acquire One Medical Retail Dispensary In Denver, Colorado, From Standing Akimbo

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SHWZ

April 18, 2023

PDF Version

DENVER, Colo., April 18, 2023 /CNW/ – Medicine Man Technologies operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), announced that it has signed definitive documents to acquire certain assets of Standing Akimbo LLC (“Standing Akimbo“). The proposed transaction includes the medical cannabis dispensary located at 3801 Jason Street in Denver, Colorado. This acquisition expands the Company’s retail consumer base and furthers its growth efforts in the Colorado market, which upon close would bring the Company’s total number of operating Colorado dispensaries to 26 (this total excludes two additional Smokey’s dispensaries previously announced for acquisition in the second quarter of 2023 as well as a Colorado Springs medical dispensary acquired in 2022).

   

The consideration for the proposed acquisition is US$10,540,000 and will be paid as US$1,000,000 in cash and US$5,540,000 in Company common stock at closing, and US$4,000,000 in deferred cash payments. The acquisition is expected to close in the third quarter of 2023 upon receipt of approval from the Colorado Marijuana Enforcement Division and local licensing authorities.

Following more than a year of medical cannabis market operating experience in New Mexico, this acquisition marks Schwazze’s concerted effort to expand operations in Colorado’s $200M+ medical cannabis market. As part of the Standing Akimbo acquisition, Schwazze plans to open a Colorado Springs medical dispensary acquired in 2022 under the Standing Akimbo banner.       

“We have tremendous respect for the Standing Akimbo brand and operators. We look forward to the team joining the Schwazze family, continue running their Denver location and also expand service by adding a second location in Colorado Springs,” said Nirup Krishnamurthy, President of Schwazze. “We look forward to utilizing Schwazze’s operating playbook to support the Standing Akimbo team in their outstanding service to the Colorado medical cannabis community.”      

Since April 2020, Schwazze has acquired, opened or announced the planned acquisition of 46 cannabis retail dispensaries (bannered as Star Buds, Emerald Fields and R. Greenleaf) as well as seven cultivation facilities and two manufacturing plants in Colorado and New Mexico. In May 2021, Schwazze announced its Biosciences division, and in August 2021 it commenced home delivery services in Colorado.

About Schwazze

Schwazze (OTCQX: SHWZ  NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit www.Schwazze.com.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/schwazze-signs-definitive-documents-to-acquire-one-medical-retail-dispensary-in-denver-colorado-from-standing-akimbo-301800128.html

SOURCE Medicine Man Technologies, Inc.

Release – Direct Digital Holdings Announces Upward Revision of Previously Published FY 2022 Earnings Press Release

Posted on by aweinsoff@channelchek.com

Research News and Market Data on DRCT

April 17, 2023 5:19pm EDT

Revision Reflects an Increase of Revenue at the Company’s Colossus SSP Subsidiary for FY 2022

Results in Full-Year Revenue of $89.4 Million, or EPS of $0.33

HOUSTON, April 17, 2023 /PRNewswire/ — Direct Digital Holdings, Inc. (Nasdaq: DRCT) (“Direct Digital Holdings” or the “Company”), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC (“Colossus SSP”), Huddled Masses LLC (“Huddled Masses”) and Orange142, LLC (“Orange142”), today announced an upward revision of the preliminary financial results originally published in its March 23, 2023 press release.

These financial results, which are reflected in the Company’s Annual Report on Form 10-K filed with the SEC today, resulted in an increase in revenues of $1.3 million over the previously published preliminary results, which increased net income to $4.2 million and increased EPS to $0.33 per share for the 12-month period ended December 31, 2022.

The updated amounts have no effect upon the cash flows for the affected periods, and will not affect forward revenue guidance for 2023 of $118 million to $122 million as issued on March 23, 2023.

About Direct Digital Holdings
Direct Digital Holdings (Nasdaq: DRCT), owner of operating companies Colossus SSP, Huddled Masses, and Orange 142, brings state-of-the-art sell- and buy-side advertising platforms together under one umbrella company. Direct Digital Holdings’ sell-side platform, Colossus SSP, offers advertisers of all sizes extensive reach within general market and multicultural media properties. The company’s subsidiaries Huddled Masses and Orange142 deliver significant ROI for middle market advertisers by providing data-optimized programmatic solutions at scale for businesses in sectors that range from energy to healthcare to travel to financial services. Direct Digital Holdings’ sell- and buy-side solutions manage approximately 90,000 clients monthly, generating over 100 billion impressions per month across display, video, CTV, in-app and other media channels. Direct Digital Holdings is the ninth black-owned company to go public in the U.S and was named a top minority-owned business by The Houston Business Journal.

Forward Looking Statements
This press release may contain forward-looking statements within the meaning of federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and which are subject to certain risks, trends and uncertainties.

As used below, “we,” “us,” and “our” refer to the Company. We use words such as “could,” “would,” “may,” “might,” “will,” “expect,” “likely,” “believe,” “continue,” “anticipate,” “estimate,” “intend,” “plan,” “project” and other similar expressions to identify forward-looking statements, but not all forward-looking statements include these words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

All of our forward-looking statements involve estimates and uncertainties that could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Our forward-looking statements are based on assumptions that we have made in light of our industry experience and our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances. Although we believe that these forward-looking statements are based on reasonable assumptions, many factors could affect our actual operating and financial performance and cause our performance to differ materially from the performance expressed in or implied by the forward-looking statements, including, but not limited to: our dependence on the overall demand for advertising, which could be influenced by economic downturns; any slow-down or unanticipated development in the market for programmatic advertising campaigns; the effects of health epidemics; operational and performance issues with our platform, whether real or perceived, including a failure to respond to technological changes or to upgrade our technology systems; any significant inadvertent disclosure or breach of confidential and/or personal information we hold, or of the security of our or our customers’, suppliers’ or other partners’ computer systems; any unavailability or non-performance of the non-proprietary technology, software, products and services that we use; unfavorable publicity and negative public perception about our industry, particularly concerns regarding data privacy and security relating to our industry’s technology and practices, and any perceived failure to comply with laws and industry self-regulation; restrictions on the use of third-party “cookies,” mobile device IDs or other tracking technologies, which could diminish our platform’s effectiveness; any inability to compete in our intensely competitive market; any significant fluctuations caused by our high customer concentration; our limited operating history, which could result in our past results not being indicative of future operating performance; any violation of legal and regulatory requirements or any misconduct by our employees, subcontractors, agents or business partners; any strain on our resources, diversion of our management’s attention or impact on our ability to attract and retain qualified board members as a result of being a public company; our dependence, as a holding company, of receiving distributions from Direct Digital Holdings, LLC to pay our taxes, expenses and dividends; and other factors and assumptions discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Conditions and Results of Operations” and other sections of our filings with the Securities and Exchange Commission that we make from time to time. Should one or more of these risks or uncertainties materialize or should any of these assumptions prove to be incorrect, our actual operating and financial performance may vary in material respects from the performance projected in these forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as required by law, we undertake no obligation to update any forward-looking statement contained in this Current Report on Form 8-K to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

View original content to download multimedia:https://www.prnewswire.com/news-releases/direct-digital-holdings-announces-upward-revision-of-previously-published-fy-2022-earnings-press-release-301799448.html

SOURCE Direct Digital Holdings

Released April 17, 2023

Blackboxstocks (BLBX) – Announces Merger; Reports 4Q22 Results

Posted on by cpereira@noblefcm.com


Tuesday, April 18, 2023

Blackboxstocks, Inc. is a financial technology and social media hybrid platform offering real-time proprietary analytics and news for stock and options traders of all levels. Our web-based software employs “predictive technology” enhanced by artificial intelligence to find volatility and unusual market activity that may result in the rapid change in the price of a stock or option. Blackbox continuously scans the NASDAQ, New York Stock Exchange, CBOE, and all other options markets, analyzing over 10,000 stocks and up to 1,500,000 options contracts multiple times per second. We provide our users with a fully interactive social media platform that is integrated into our dashboard, enabling our users to exchange information and ideas quickly and efficiently through a common network. We recently introduced a live audio/video feature that allows our members to broadcast on their own channels to share trade strategies and market insight within the Blackbox community. Blackbox is a SaaS company with a growing base of users that spans 42 countries; current subscription fees are $99.97 per month or $959.00 annually. For more information, go to: www.blackboxstocks.com .

Joe Gomes, Managing Director – Generalist Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Merger. Blackboxstocks announced its intent to merger with Evtec Group. BLBX shareholders are expected to retain 8.34% of the combined company’s common stock post-merger. While details of the transaction are limited, management believes the transaction will provide significant and long-term value for BLBX shareholders. Blackboxstocks will operate as a subsidiary of Evtec. In its just filed 10-K for 2022, the Company noted it was exploring strategic alternatives.

Who Is Evtec Group? A private U.K.-based company, Evtec Group is a leading parts supplier for luxury brands in the EV and performance automotive market. The acquisition of Blackboxstocks provides Evtec with a pathway to become publicly traded in the U.S., while enabling Blackboxstocks access to capital needed to take the next step forward in its business, in our view.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Regulate AI?  Elon Musk Thinks it’s an Intelligent Idea

Posted on by phoffman@channelchek.com
Image Credit: Steve Jurvetson (Flickr)

Elon Musk Unveils How He Expects to Approach Artificial Intelligence

The CEO of SpaceX, Twitter, Tesla, as well as the founder of The Boring Company , and Neuralink, says he wants to do something to serve humanity. Elon Musk has been concerned that artificial intelligence may have the propensity to turn against mankind. He said the best way to avoid the problem is to make artificial intelligence curious. “I’m going to start something which I call ‘TruthGPT’ or a maximum truth-seeking AI that tries to understand the nature of the universe,” Musk said in an interview with Tucker Carlson. The billionaire thinks that an AI that cares about understanding the universe is “unlikely to annihilate humans” as we’re an “interesting part of the universe, hopefully.” During the discussion, he emphasized the project will differ from competitors, such as OpenAI’s ChatGPT and Google’s Bard, by caring about understanding the universe.

This ambitious new goal of Musk’s was introduced with few details about the project, so it remains unclear how, exactly a machine becomes curious. He did repeat that he considers AI dangerous if mismanaged, with a “potential for civilizational destruction.” In fact, he called for some level of government oversight over AI projects. Musk isn’t new to the technology; he is actually one of the co-founders of OpenAI, the company that has been making headlines with its AI chatbot named ChatGPT.

The new technology would likely compete with AI efforts by Sam Altman-led OpenAI, which as mentioned was initially funded by Musk, Google’s DeepMind, and other AI initiatives around the world.

Regulating A.I.

Musk told Carlson he envisions a regulatory agency that “initially seeks insight into AI, then solicits opinion from industry, and then has proposed rule-making,” something like the Federal Aviation Administration and how it interacts with aviation and aerospace companies. Once agency and industry-accepted rules in place, “I think we’ll have a better chance of advanced AI being beneficial to humanity,” Musk said. Musk signed a letter calling for a pause on advanced AI research because he is part of a group of signers that believe it can potentially harm society.

“Contemporary AI systems are now becoming human-competitive at general tasks, and we must ask ourselves: Should we let machines flood our information channels with propaganda and untruth?” the letter stated.

Part two of the interview is scheduled to air at 8 PM ET April 18 on Fox News.

Paul Hoffman

Managing Editor, Channelchek

https://www.foxnews.com/media/elon-musk-develop-truthgpt-warns-civilizational-destruction-ai

https://www.cnbc.com/2023/04/18/musk-calls-plans-truthgpt-ai-to-rival-openai-deepmind.html

Are Select Biotech Stocks on the Launchpad?

Posted on by phoffman@channelchek.com
Image Credit: Hagerstown CC (Flickr)

Why Biotech Stocks Experience Significant Price Moves

Has biotech reached the tipping point? Shares of PromethiusBiosciences (RXDX) are up 70% this week after Merck (MRK) announced on Sunday it will pay a 75% premium for the clinical-stage biotech company. This follows last month’s big news when Pfizer announced its intention to acquire Seagen (SGEN), on the same day Sanofi (SNY) announced plans to buy Provention Bio (PRVB). This sent PRVB shares skyrocketing 258%. The question for biotech investors now is, who’s next?

Drug discovery and development is a long, uncertain path that often takes 10–15 years, and costs that could exceed $1–2 billion for any new drug ultimately approved for clinical use. Unlike unregulated products, it’s a significant achievement for a candidate to get as far as clinical trials. Promethius and Provention are both clinical-stage biotech companies. Fortunately for investors, each step along the path to success, whether or not it leads to a product going to market, can cause a significant swing in the stock’s price.

Small-cap biotech stocks can experience these significant price jumps from a variety of events. During the period of research and development, a drug on the path toward success or failure will have other significant events both positive and negative, that will impact the stock price in ways not found in other industry sectors. Here are some examples:

Positive clinical trial results: When a small-cap biotech company releases positive clinical trial results, it can generate significant investor interest and drive up the stock price.

Acquisition rumors or deals: When rumors or announcements of an acquisition by a larger company circulate, it can cause a small-cap biotech stock to rise as investors anticipate a potential buyout premium.

FDA approvals: FDA approvals of drugs or medical devices can significantly boost a small-cap biotech company’s stock price, as it can open up a new revenue stream for the company.

Partnerships and collaborations: Partnerships and collaborations with larger companies can also cause a small-cap biotech stock to rise as it indicates a level of validation for the company’s technology or products.

Analyst upgrades: If an influential analyst upgrades their rating on a small-cap biotech stock, it can increase investor interest and drive up the stock price.

Companies You May Want to Watch

There is information on well-over 200 small-cap biotech companies on Channelchek. Below is a select group that investors may want to follow.  

Cocrystal (COCP): Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses.

Axcella (AXLA): Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator compositions. The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis.

Tonix Pharmaceutical (TNXP): Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system, rare disease, immunology and infectious disease product candidates.

Onconova Therapeutics (ONTX):   Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

MAIA Biotechnology (MAIA):   MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of cancer patients.

PDS Biotechnology (PDSB):    PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on proprietary T cell-activating technology platforms.

Ocugen (OCGN): Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company impacts patient’s lives through innovation that forge new scientific paths.

Take Away

Biotech stocks, especially small-caps have come well off the pandemic era, sky-high price levels they had attained. At the same time, large pharmaceutical companies that are still seeing sales from covid related products have ample cash and are faced with patents that are always inching closer to expiration. Acquisitions tend to cause huge price spikes in all industries, especially biotech.

While pharmaceutical companies will be picky as they may work to own patents on their next generation of product offerings, many other positive (and negative) occurrences could impact the stock price. Channelchek provides current information on small-cap biotech stocks so that investors can determine the likelihood of success and to help them steer from negative investment results.

Paul Hoffman

Managing Editor, Channelchek

Sources

https://www.channelchek.com/search-new?search=biotech

https://www.fiercebiotech.com/biotech/big-pharma-resisting-temptation-biotech-ma-until-prices-drop-further

https://seekingalpha.com/article/4594550-catalyst-pharmaceuticals-a-one-hit-wonder-with-upside

Release – Direct Digital Holdings to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & 1×1 Meetings on Thursday, April 27, 2023

Posted on by aweinsoff@channelchek.com

Research News and Market Data on DRCT

April 17, 2023 9:00am EDT

HOUSTON, TX / ACCESSWIRE / April 17, 2023 / Direct Digital Holdings, Inc (Nasdaq:DRCT) (“Direct Digital Holdings” or the “Company”) , a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC (“Colossus SSP”), Huddled Masses LLC (“Huddled Masses”) and Orange142, LLC (“Orange142”), today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 at 2:30PM (Local Time – PST). President & Co-Founder of Direct Digital Holdings, Keith Smith, and Chief Financial Officer of Direct Digital Holdings, Susan Echard, will be hosting the presentation and answering questions at the conclusion. The Company will also be hosting 1×1 meetings on Thursday, April 27, 2023.

To access the live presentation, please use the following information:

Planet MicroCap Showcase: VEGAS 2023

Date: Wednesday, April 26, 2023

Time: 5:30 PM Eastern Time (2:30 PM Pacific Time)

Direct Digital Holdings continues to demonstrate robust financial performance, significant operational expansion and continued gains in market share as it capitalizes on strong macroeconomics tailwinds in digital advertising and media. The Company continues to implement strategic growth initiatives to position the Company to continue to deliver high-quality, technology-led digital advertising solutions to its expanding customer network. Direct Digital Holdings is the ninth black-owned company to go public in the U.S. and is pioneering the AdTech space as a leader in programmatic advertising leveraging its technology and strategy to focus on reaching consumers and publishers in mid-sized and multicultural markets. The Company recently released a whitepaper conducted by Horowitz research that garnered key insights into the importance on effectively engaging with diverse communities and media properties.

If you would like to book 1×1 investor meetings with Direct Digital Holdings, and to attend the Planet MicroCap Showcase: VEGAS 2023, please make sure you are registered here: https://planetmicrocapshowcase.com/signup

1×1 meetings will be scheduled and conducted in person at the conference venue in LAS VEGAS.

The Planet MicroCap Showcase: VEGAS 2023 website is available here: https://planetmicrocapshowcase.com/

News Compliments of Accesswire

About Direct Digital Holdings

Direct Digital Holdings (Nasdaq: DRCT), owner of operating companies Colossus SSP, Huddled Masses, and Orange 142, brings state-of-the-art sell- and buy-side advertising platforms together under one umbrella company. Direct Digital Holdings’ sell-side platform, Colossus SSP, offers advertisers of all sizes extensive reach within general market and multicultural media properties. The company’s subsidiaries Huddled Masses and Orange142 deliver significant ROI for middle market advertisers by providing data-optimized programmatic solutions at scale for businesses in sectors that range from energy to healthcare to travel to financial services. Direct Digital Holdings’ sell- and buy-side solutions manage approximately 90,000 clients monthly, generating over 100 billion impressions per month across display, CTV, in-app and other media channels. Direct Digital Holdings is the ninth black-owned company to go public in the U.S and was named a top minority-owned business by The Houston Business Journal.

About Planet MicroCap

Planet MicroCap is a global multimedia financial news, publishing and events company focused on news dissemination, providing information, data and analytics for the MicroCap investing community. We have cultivated an active and engaged audience of folks that are interested in learning about and to stay ahead of the curve in the MicroCap space.

If you would like to attend the Planet MicroCap Showcase, please register here: https://planetmicrocapshowcase.com/signup

Contact:

Name: Brett Milotte, ICR for Direct Digital Holdings
Email: Brett.Milotte@icrinc.com

SOURCE: Direct Digital Holdings via SNN Network



View source version on accesswire.com:
https://www.accesswire.com/749444/Direct-Digital-Holdings-to-Present-at-the-Planet-MicroCap-Showcase-VEGAS-2023-on-Wednesday-April-26-2023-1×1-Meetings-on-Thursday-April-27-2023

Released April 17, 2023

Release – Century Lithium Provides Update On Collaboration With Koch Technology Solutions

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CDYVF

April 17, 2023 – Vancouver, Canada – Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) (“Century Lithium” or “the Company”) is pleased to report that further to its news release dated February 9, 2023, the Company has received from Koch Technology Solutions’ (“KTS”) equipment for KTS’ Li-Pro™ process for direct lithium extraction (“DLE”). The KTS equipment has been installed and is now operating at Century Lithium’s Lithium Extraction Facility (“Pilot Plant”) in Amargosa Valley, Nevada, USA.

The collaboration between Century Lithium and KTS begins a field trial of KTS’ Li-Pro™ equipment to treat the process solutions generated at the Pilot Plant in the leaching of bulk sample claystone collected from the Company’s Clayton Valley Lithium Project (“Project”). Following successful installation, operation of KTS’ equipment went very well throughout an initial 7-day start-up.  Results from the program will enable KTS to provide engineering and cost data to Century Lithium for a full-scale installation of the DLE plant in Century Lithium’s Project.

About Koch Technology Solutions

Koch Technology Solutions (KTS) is the technology licensing business of Koch Engineered Solutions (KES). KTS creates value for its customers across a growing portfolio of technologies including direct lithium extraction, the polyester value chain, refining industry and 1,4-Butanediol plus its derivatives. KTS combines its exclusive technologies, expertise, and capabilities with those of other KES companies to provide overall solutions to optimize customers’ capital investments and existing manufacturing assets.

About Century Lithium Corp.

Century Lithium Corp. (formerly Cypress Development Corp.) is an advanced stage lithium company, focused on developing its 100%-owned Clayton Valley Lithium Project in west-central Nevada, USA. Century Lithium is currently in the pilot stage of testing on material from its lithium-bearing claystone deposit at its Lithium Extraction Facility in Amargosa Valley, Nevada and progressing towards completing a Feasibility Study and permitting, with the goal of becoming a domestic producer of lithium for the growing electric vehicle and battery storage market.

ON BEHALF OF CENTURY LITHIUM CORP.
WILLIAM WILLOUGHBY, PhD., PE
President & Chief Executive Officer

For further information, please contact:
Spiros Cacos | Vice President, Investor Relations
Direct: +1 604 764 1851
Toll Free: 1 800 567 8181
scacos@centurylithium.com 
centurylithium.com  

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

Cautionary Note Regarding Forward-Looking Statements

This release includes certain statements that may be deemed to be “forward-looking statements”. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects,” “estimates,” “projects,” “anticipates,” “believes,” “could,” “scheduled,” and other similar words. All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration, and development successes, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at www.sedar.com for further information.

Release – Comtech Secures Strategic Contracts for Hybrid Designed High-Speed SATCOM Solution

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CMTL

Apr 17, 2023 9:08 AM

MELVILLE, N.Y. –
April 17, 2023– Comtech announced today that the company recently secured multiple orders for significant quantities of its CDM-780 high-speed software defined modems. These modems will be delivered to innovative, next generation satellite operators as well as to the U.S. Department of Defense who will be assessing, evaluating, and fielding these modems in a variety of scenarios to enable broad scale government and commercial deployments to provide end users with access to high-speed connectivity in some of the hardest to reach places in the world.

“Our CDM-780 is uniquely positioned to support the blending of communications services across multiple, diverse satellite orbits and networks,” said Ken Peterman, President and CEO, Comtech. “These contracts illustrate our continuing technology leadership and fluency in future networking capabilities that can help our customers democratize access to communications and empower individuals, communities, businesses, and governments across the globe.”

Comtech’s CDM-780 is one of the highest capacity commercial off the shelf gateway SATCOM solutions available today. Through a software-defined architecture, the CDM-780 is designed to readily adapt and evolve over time to deliver SATCOM services that can transition across high throughput and very high throughput satellite networks, as well as Low Earth Orbit, Medium Earth Orbit, and Geostationary Earth Orbit constellations.

About Comtech

Comtech Telecommunications Corp. is a leading global technology company providing space and satellite communications technologies, terrestrial and wireless network solutions, next-generation 9-1-1 emergency services, and cloud native capabilities to commercial and government customers around the world. Our unique culture of innovation and employee empowerment unleashes a relentless passion for customer success. With multiple facilities located in technology corridors throughout the United States and around the world, Comtech leverages our global presence, technology leadership, and decades of experience to create the world’s most innovative communications solutions.For more information, please visit www.comtech.com.

Forward-Looking Statements

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results and performance could differ materially from such forward-looking information. The Company’s Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.

PCMTL

View source version on businesswire.com: https://www.businesswire.com/news/home/20230416005073/en/

Investor Relations

Robert Samuels

631-962-7102

robert.samuels@comtech.com

Media

Jamie Clegg

480-532-2523

jamie.clegg@comtech.com

Release – Kratos and ALL.SPACE to Work Together to Develop Advanced Terminal Solutions for Software-Defined Satellite Ground Systems

Posted on by aweinsoff@channelchek.com

Research News and Market Data on KTOS

April 17, 2023 at 8:00 AM EDT

PDF Version

Partnership Focuses on Delivering Fully Digital-Enabled Edge Terminal Solutions

SAN DIEGO and READING, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company specializing in defense, national security and communications solutions, and ALL.SPACE, the world’s only provider of multi-orbit smart terminals, announced today a strategic partnership aimed at jointly developing and delivering solutions that will enable software-defined satellite ground systems to better leverage the capabilities of next-generation smart terminals. The combined solutions are expected to enhance dynamic operations end-to-end across the ground segment from the gateway to the network’s edge, placing more application power in the hands of end users and greatly expanding flexibility beyond today’s proprietary, purpose-built, satellite terminals.

The space industry is immersed in a renaissance driven by technology breakthroughs such as software-defined payloads, small satellite constellations, multi-orbit services and more. On the ground, advances in satellite networks are occurring as well, including the growth of ground station-as-a-service, virtualized ground systems and the need to better mainstream with terrestrial and cellular communications networks. These advances at both ends of the space/ground connection mean that satellite network systems must come to act more dynamically, adapting on-the-fly to changing needs, conditions and business or mission requirements.

Today’s announcement is part of a multi-year collaboration to integrate and enhance both companies’ products. It is supported by a joint development roadmap focused on new features, functions and capabilities that will deliver more powerful, flexible and agile terminal capabilities at the network’s edge for both defense and commercial uses, such as advanced support for multi-mission and multi-orbit capabilities.

According to Greg Quiggle, Senior Vice President of Space Product Management at Kratos, “Historically, satellite terminals have been defined by proprietary technologies resident on purpose-built hardware, severally limiting what users could accomplish at the network’s edge. That all changes with software-defined networking, which has long been the standard in global terrestrial communications and is now available for satellite network operators through the OpenSpace Platform. ALL.SPACE is a leader in smart terminal technology and a profound partner for Kratos to work with in revolutionizing what users can accomplish at the satellite network’s edge.”

“We are creating a new generation of digital, flexible terminals featuring both a multi-beam antenna and a platform capable of hosting software-defined applications,” said John-Paul Szczepanik, Chief Technology Officer for ALL.SPACE. “ALL.SPACE’s multilink terminal delivers the combined strengths of all orbits by unlocking simultaneous access to multiple networks. We believe pairing this flexibility with the Kratos OpenSpace Platform will dramatically enhance dynamic operations at the edge.”

Kratos and ALL.SPACE have already begun integrating their respective technologies, including elements of Kratos’ OpenSpace® software-defined ground system, such as its OpenSpace virtual modem (vModem) and OpenEdge™ 2500 digitizer, with ALL.SPACE’s S2000 Smart Terminal.

The jointly developed solutions will conform to industry standards for maximum flexibility, including the IEEE-ISTO Std 4900-2021: Digital IF Interoperability Standard from the Digital IF Interoperability (DIFI) Consortium (DIFI). Both companies believe that common standards are essential for the space industry to realize the opportunities on the horizon and to advance the industry’s integration with the larger global communications infrastructure. Both are founding members of DIFI, an independent organization created to develop and promote standards for interoperability in space and satellite systems.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology company that develops and fields transformative, affordable systems, products and solutions for United States National Security, its allies and global commercial enterprises. At Kratos, affordability is a technology, and Kratos is changing the way breakthrough technology is rapidly brought to market with actual products, systems and technologies rather than slide decks or renderings. Through proven commercial and venture capital backed approaches, including proactive, internally funded research and streamlined development processes, Kratos is focused on being first to market with our solutions, well in advance of competition. Kratos is the recognized Technology Disruptor in our core market areas, including Space and Satellite Communications, Cyber Security and Warfare, Unmanned Systems, Rocket and Hypersonic Systems, Next-Generation Jet Engines and Propulsion Systems, Microwave Electronics, C5ISR and Virtual and Augmented Reality Training Systems. For more information, visit www.KratosDefense.com.

About ALL.SPACE
Headquartered in Reading, UK, ALL.SPACE is the first and only field-proven platform to simultaneously deliver full-performance connections across all significant orbits from a single device. The company recently concluded live field tests with the US and UK governments and several satellite operators demonstrating multiple, simultaneous connections across LEO, MEO and GEO orbits, which empowers users in markets ranging from government and defence to maritime, aero and land mobile to harness the full benefits of new satellite constellations and the convergence of GEO and NGSO (Non-Geostationary Orbit) services. 

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 25, 2022, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the by Kratos.

Kratos Press Contact:
Yolanda White
858-812-7302 Direct

Kratos Investor Information:
877-934-4687
investor@kratosdefense.com

ALL.SPACE Press Contact:
Anne Wainscott-Sargent
404-435-5784
media@all.space

Source: Kratos Defense & Security Solutions, Inc.

Release – CoreCivic Releases Fifth Annual ESG Report Showcasing 40 Years of Operational Excellence and Continued Commitment to Reentry

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CXW

April 17, 2023

Company Has Launched New ‘Lived Experience’ Reentry Programs in Past Year

BRENTWOOD, Tenn., April 17, 2023 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (the Company) today released its 2022 Environmental, Social and Governance (ESG) report. The Company’s fifth annual report illustrates CoreCivic’s longstanding commitment to operating safely, ethically and transparently while making a positive impact on the communities it serves together with government partners.

“CoreCivic’s durability over the last 40 years reveals our character, and that shows in our progress toward our ESG goals,” said Damon Hininger, president and CEO, CoreCivic. “I’m proud of the way our first-class staff have continually innovated over the years, and especially in 2022, to serve our government partners dependably, compassionately and with excellence.”

The 2022 report details CoreCivic’s commitments and progress toward goals in safe and secure operations; reentry services; innovative solutions delivery; health services; talent attraction; diversity, equity and inclusion (DE&I); and more.

The Company’s approach to reentry services has grown to include several new programs and others in the pipeline that involve residents learning from the “lived experience” of others who have been incarcerated. CoreCivic staff and leaders are rising to meet the threat posed by dangerous contraband such as opioids. The Company has invested in mental health resources to help keep residents safe and delivered human rights training to 97 percent of continuing employees. By diversifying its supply chain, CoreCivic has created more opportunities than ever for women-and minority-owned businesses to partner with the Company. Wages were also increased for nearly all facility staff not already covered by the wage determination process in federal contracts.

CoreCivic also realigned its internal structure in 2022, combining real estate operations with community corrections operations and naming Executive Vice President Lucibeth Mayberry as Chief Innovation Officer.

Mayberry’s team is already making positive impacts on the wellbeing of residents and staff. For example, thanks to the innovation team, CoreCivic offered alternative housing options for staff to combat the national housing shortage in the U.S. The team helped create a normalization process for easing residents out of a correctional environment by transitioning to more home-like surroundings. And it launched a collaboration with government partners to provide free tablets to residents to promote easier contact with family and loved ones, an essential component of successful reentry.

GI Jobs has recognized CoreCivic as a Military Friendly Employer for the 12th consecutive year, conferring Gold Status on the Company. CoreCivic also received a 30 percent year-over-year increase in employment applications. And it connected more than 600 community volunteers with facility residents and staff to help facilitate successful reentry through partnerships like the Frederick Douglass Project for Justice, the Maverick City Music Initiative and second chance hiring firm Cornbread Hustle.

The Company also advocated for recidivism-reducing policies in nine states, including a successful South Carolina state tax credit for hiring formerly incarcerated individuals. Since launching this public policy initiative in 2017, CoreCivic has sent 2,883 letters to federal and state officials in support of 113 reentry-friendly bills with 20 pieces of legislation signed into law.

“There’s a lot to be proud of in the work CoreCivic did in 2022 and over the last 40 years,” Hininger said. “We’ve succeeded, and expect to keep succeeding, because we’re willing to learn from each other, from our residents, and from the agencies, groups, and institutions who serve as our partners.”

About CoreCivic
CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believe we are the largest private owner of real estate used by U.S. government agencies. We have been a flexible and dependable partner for government for more than 40 years. Our employees are driven by a deep sense of service, high standards or professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Contact: Investors: Cameron Hopewell – Managing Director, Investor Relations – (615) 263-3024
Financial Media: David Gutierrez, Dresner Corporate Services – (312) 780-7204

Release – Tonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft Survival

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TNXP

April 17, 2023 7:00am EDT

Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital

CHATHAM, N.J., April 17, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the on-line publication of two papers1,2 in the American Journal of Transplantation by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in collaboration with Tonix Pharmaceuticals. The data involve studies of Tonix’s TNX-1500 (Fc-modified anti-CD40L humanized monoclonal antibody [mAb]) product candidate in development for the prevention of organ transplant rejection. The molecular target of TNX-1500 is CD40-ligand (CD40L), which is also known as CD154, T-BAM or 5c8 antigen. The publications include data demonstrating that TNX-1500 showed activity in preventing organ rejection and was well tolerated in non-human primates. Blockade of CD40L with TNX-1500 monotherapy consistently and safely prevented pathologic alloimmunity in non-human primate models of cardiac and kidney allograft model without clinical thrombosis.

“There remains a significant need for new treatments with improved activity and tolerability to prevent organ transplant rejection,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “To date, there has not been a humanized anti-CD40L antibody that can effectively prevent transplant rejections with an acceptable level of tolerability. TNX-1500 is a third generation anti-CD40L mAb that has been designed by protein engineering to decrease FcγRII binding and to reduce the potential for thrombosis. The animal studies found that TNX-1500 retains activity to prevent rejection and preserve graft function. Tonix expects to start a first-in-human Phase 1 study in the second quarter of 2023 of TNX-1500 for prophylaxis of organ rejection in adult patients receiving a kidney transplant.”

Tatsuo Kawai, M.D., Ph.D., A. Benedict Cosimi Chair in Transplant Surgery, MGH and Professor of Surgery, Harvard Medical School (HMS) and senior author of the kidney transplant publication, said, “The blockade of the CD40L-CD40 pathway with anti-CD40L mAbs has been the most promising immunomodulatory approach to prevent allograft rejection. However, long-term graft and patient survival following transplantation of kidneys and other solid organs are constrained by side effects of the existing medications. Our data demonstrate a favorable safety profile associated with TNX-1500, since neither non-human primate nor human platelet activation were observed in-vitro when exposed to TNX-1500-sCD40L immune complexes. The therapeutic effects of TNX-1500 to consistently inhibit rejection of mismatched kidney allografts were not associated with infectious or thromboembolic complications, suggesting that clinical studies are warranted to evaluate TNX-1500 for transplant indications.”

Richard N. Pierson III, M.D., scientific director of the Center for Transplantation Sciences in the Department of Surgery at MGH and Professor of Surgery at HMS and senior author of the heart transplant paper said, “Anti-CD40L therapy has a unique activity in controlling the immune response to organ transplants. There remains a significant need for new treatments with improved activity and tolerability to prevent or treat organ transplant rejection. Anti-CD40L has shown great promise to facilitate transplant tolerance in multiple preclinical transplant models.  A safe, effective anti-CD40L also has potential to enable use of genetically modified or humanized pig organs to treat humans with advanced organ failure or diabetes, an emerging field known as xenotransplantation.”

Tonix Pharmaceuticals Holding Corp.*

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with topline data expected in the fourth quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Enrollment in a Phase 2 study has been completed, and topline results are expected in the third quarter of 2023. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is currently enrolling with topline data expected in the fourth quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets), a once-daily formulation of tianeptine being developed as a treatment for major depressive disorder (MDD), is also currently enrolling with interim data expected in the fourth quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the second quarter of 2023. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox, for which a Phase 1 study is expected to be initiated in the second half of 2023. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases. The infectious disease portfolio also includes TNX-3900, a class of broad-spectrum small molecule oral antivirals.

*All of Tonix’s product candidates are investigational new drugs or biologics and none has been approved for any indication.

1Lassiter, G., et al. (2023). TNX-1500, a crystallizable fragment–modified anti-CD154 antibody, prolongs nonhuman primate renal allograft survival. American Journal of Transplantation. April 3, 2023. https://doi.org/10.1016/j.ajt.2023.03.022

2Miura, S., et al. (2023) TNX-1500, a crystallizable fragment–modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival. American Journal of Transplantation. April 6, 2023. https://doi.org/10.1016/j.ajt.2023.03.025

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2023, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com
(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Source: Tonix Pharmaceuticals Holding Corp.

Released April 17, 2023

Release – Orion Group Holdings, Inc. to Report First Quarter Financial Results on Monday, May 8

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ORN

Apr 17, 2023

Conference Call to be held Tuesday, May 9 at 8:00 a.m. Central Time

HOUSTON, April 17, 2023 (GLOBE NEWSWIRE) — Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”), a leading specialty construction company, today announced that it will issue its financial results for the first quarter ended March 31, 2023 on Monday, May 8, 2023, after the close of the stock market.

A conference call and audio webcast with analysts and investors will be held the next day, May 9, at 8:00 a.m. Central Time to discuss the results and answer questions.

Live conference call: 800-715-9871

Live and archived webcast: https://edge.media-server.com/mmc/p/7kn5kim4 or the Company’s website at Orion Group Holdings, Inc. – Investor Relations & Shareholder Contact (oriongroupholdingsinc.com)

About Orion Group Holdings, Inc.

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental United States, Alaska, Canada and the Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including place and finish, site prep, layout, forming, and rebar placement for large commercial, structural and other associated business areas. The Company is headquartered in Houston, Texas with regional offices throughout its operating areas.

Contacts:

Financial Profiles, Inc.
Margaret Boyce 310-622-8247
ORN@finprofiles.com

Ocugen (OCGN) – Positive Preliminary Data Shows Proof-Of-Concept For OCU400

Posted on by cpereira@noblefcm.com


Monday, April 17, 2023

Ocugen, Inc. is a biotechnology company focused on developing and commercializing novel gene therapies, biologicals, and vaccines. The lead product, Covaxin, is a killed-virus vaccine for COVID-19 in-licensed from Bharat Biotech (India). The lead product in its gene therapy program, OCU400, is in Phase 1/2 clinical trials for retinitis pigmentosa.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Preliminary Data Shows Proof-Of-Concept. Ocugen reported preliminary data from its Phase 1/2 trial testing OCU400 gene therapy in retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA).  The study was designed to establish safety and  test increasing dosage using trial endpoints designed to measure vision in low light and visual acuity. Patient responses showed improvements in function, with safety and tolerability. We see this as an important proof-of-concept for OCU400 and Ocugen’s gene therapy technology.

Data Showed Functional Improvements In Vision. The data presented was from a preliminary analysis of 7 patients in the first two cohorts who received the low and medium doses. These patients had either of two retinitis pigmentosa mutations, RHO or NR2E3. The outcome measures presented were the multi-luminance mobility test (MLMT), a measure of the ability to detect levels of light, and BCVA (best corrected visual acuity).


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.